New data presented at Psych Congress Elevate 2025 by Teva Pharmaceuticals reveals significant rates of undertreated tardive dyskinesia, particularly in long-term care settings. Tardive dyskinesia is a serious condition often resulting from long-term use of antipsychotic drugs, and the findings underscore a critical gap in treatment, highlighting the need for improved management strategies in healthcare facilities. According to the study, a substantial number of patients in long-term care are not receiving adequate treatment for this condition, exacerbating their symptoms and impacting their quality of life. The insights from Teva’s research could prompt policy changes and encourage healthcare providers to focus more on monitoring and treating this often-overlooked side effect. These revelations are poised to inform both medical practices and patient care protocols, driving a more holistic approach to managing mental health conditions. By addressing the prevalence of tardive dyskinesia in such settings, stakeholders can improve patient outcomes and quality of care, ensuring more comprehensive and attentive treatment regimens.
Yahoo FinanceNew data shows 90% of buyers unable to afford new Brisbane apartments
April 29, 2026
In Brisbane, a startling new statistic reveals that nine out of ten potential buyers are priced out of the city’s new apartment market. With soaring